The UK National Institute For Health And Care Excellence Issues Final Draft Guidance To Provide Patients With A Natural Lens Being Treated For Chronic Diabetic Macular Edema Access To ILUVIEN
Portfolio Pulse from Benzinga Newsdesk
The UK's National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending ILUVIEN for chronic diabetic macular edema (DME) in patients with a natural lens. Alimera Sciences, Inc. (NASDAQ:ALIM), the producer of ILUVIEN, views this as a significant step forward, potentially benefiting up to 75% of the DME population in the UK. Final Guidance will be published after February 22, 2024, and NHS England and Wales have committed to funding the treatment shortly after publication.
February 08, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alimera Sciences, Inc. (ALIM) receives positive Final Draft Guidance from NICE for ILUVIEN in treating chronic DME, potentially impacting a significant portion of the DME population in the UK.
The positive Final Draft Guidance from NICE for ILUVIEN represents a significant regulatory milestone for Alimera Sciences, potentially increasing its market share and revenues in the UK. Given the large portion of the DME population this decision affects, it's likely to have a positive short-term impact on ALIM's stock price. The commitment from NHS England and Wales to fund the treatment further solidifies the positive outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100